Free Trial
NASDAQ:MBOT

Microbot Medical Q4 2025 Earnings Report

Microbot Medical logo
$1.84 -0.12 (-6.12%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 -0.02 (-1.09%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microbot Medical EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Microbot Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Microbot Medical Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Microbot Medical's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules.

Conference Call Resources

Microbot Medical Earnings Headlines

SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.

View Microbot Medical Profile